Skip to content
About Us
About Us
Careers
Contact Us
Pipeline
Partnership
Licensing
Updates
Updates
Search
Search
Updates
All Resources
Press Releases
Videos
All Resources
Press Releases
Videos
Press Releases
Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory Diseases
Read Article
Press Releases
Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory Diseases
Read Article
Clear search querie